Table 2 Most common treatment-related adverse events per patient

From: Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

  Grade 1/2 Grade 3/4 Total
  N % N % N %
Diarrhoea 29 63 3 7 32 70
Asthenia 28 61 3 7 31 67
Nausea 26 57 4 9 30 65
Vomiting 22 48 3 7 25 54
Alopecia 19 41 6 13 25 54
Mucositis 20 44 1 2 21 46
Anaemia 20 43.5 20 44
Hand–foot skin reaction 17 37 1 2 18 39
Bleeding 17 37 17 37
Constipation 7 15 2 4 9 20
Neutropenia 6 13 1 2 7 15
Proteinuria 6 13 6 13
Epigastralgia 6 13 6 13
Anorexia 5 11 5 11
Headache 5 11 5 11
Fever 5 11 5 11